Literature DB >> 405504

Leishmaniasis in Brazil: XII. Observations on cross-immunity in monkeys and man infected with Leishmania mexicana mexicana, L. m. amazonensis, L. braziliensis braziliensis, L. b. guyanensis and L. b. panamensis.

R Lainson, J J Shaw.   

Abstract

Cross-immunity trials in monkeys (Cebus apella apella) and observations on experimental and natural infections in man confirm the separate identity of L. mexicana mexicana, L. m. amazonensis, L. b. braziliensis, L. b. guyanensis and L. b. panamensis. Neither L. m. mexicana nor L. m. amazonensis infections gave protection against subsequent challenge with parasites of the L. braziliensis complex; but recovery from infection with subspecies of L. braziliensis in most cases gave firm resistance to infection with the mexicana parasites. The failure of certain New World leishmanias to immunize against each other has an important bearing on taxonomy, future attempts to prepare vaccines against Leishmania, epidemiology and diagnosis.

Entities:  

Mesh:

Year:  1977        PMID: 405504

Source DB:  PubMed          Journal:  J Trop Med Hyg        ISSN: 0022-5304


  8 in total

1.  Multifunctional CD4⁺ T cells in patients with American cutaneous leishmaniasis.

Authors:  A B B Macedo; J C Sánchez-Arcila; A O Schubach; S C F Mendonça; A Marins-Dos-Santos; M de Fatima Madeira; T Gagini; M I F Pimentel; P M De Luca
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

2.  Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis.

Authors:  Beatriz Coutinho De Oliveira; Malcolm S Duthie; Valéria Rêgo Alves Pereira
Journal:  Hum Vaccin Immunother       Date:  2019-11-11       Impact factor: 3.452

3.  Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.

Authors:  Ingrid Aguilar-Be; Renata da Silva Zardo; Edilma Paraguai de Souza; Gulnara Patrícia Borja-Cabrera; Miguel Rosado-Vallado; Mirza Mut-Martin; Maria del Rosario García-Miss; Clarisa Beatriz Palatnik de Sousa; Eric Dumonteil
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

4.  Cutaneous Infection with Leishmania major Mediates Heterologous Protection against Visceral Infection with Leishmania infantum.

Authors:  Audrey Romano; Nicole A Doria; Jonatan Mendez; David L Sacks; Nathan C Peters
Journal:  J Immunol       Date:  2015-09-14       Impact factor: 5.422

5.  Membrane glycoprotein M-2 protects against Leishmania amazonensis infection.

Authors:  J Champsi; D McMahon-Pratt
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

6.  Development of Vaccines against Visceral Leishmaniasis.

Authors:  Krystal J Evans; Lukasz Kedzierski
Journal:  J Trop Med       Date:  2011-09-05

7.  A common major surface antigen on amastigotes and promastigotes of Leishmania species.

Authors:  V Colomer-Gould; L Glvao Quintao; J Keithly; N Nogueira
Journal:  J Exp Med       Date:  1985-09-01       Impact factor: 14.307

Review 8.  Cutaneous Leishmaniasis Vaccination: A Matter of Quality.

Authors:  Paula Mello De Luca; Amanda Beatriz Barreto Macedo
Journal:  Front Immunol       Date:  2016-04-21       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.